Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing

Share Article

Selexis SA Is the First Biotechnology Company to Deliver Manufacturing-Ready Research Cell Banks with a Fully Sequenced Genome and Transcriptome

Next-Generation Sequencing

Next-Generation Sequencing

Our customers will now have unprecedented tools that can decrease biologic manufacturing risks from point mutations to the introduction of adventitious agents.

Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks (RCBs) used for drug discovery to commercial manufacturing, announced today all Selexis generated Research Cell Banks will include Next-Generation Sequencing (NGS) data packages. The NGS analysis of the cell’s genetic architecture de-risks biologic manufacturing by ensuring the integrity of the gene, validation of the left and right integration sites and providing a comprehensive genetic baseline that allows for a novel way to code and trace the RCB with a reference point for cumulative mutations and other genetic changes.

“With the advent of faster, more cost-effective Next-Generation Sequencing technologies combined with our exclusive bioinformatics tools, we now have the ability to quickly analyze and assemble the genetic architecture of any Selexis generated Research Cell Bank. The analysis gives us major knowledge and insight into the genome and transcriptome of our CHO K1 cell line,” said Dr. Igor Fisch, CEO, Selexis SA. “Our customers will now have unprecedented tools that can decrease biologic manufacturing risks from point mutations to the introduction of adventitious agents.”

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies for biologic drug discovery and mammalian Research Cell Banks for scale-up to manufacturing of recombinant therapeutic proteins. With the Company’s SUREtechnology Platform™ biopharmaceutical companies can significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for the production of monoclonal antibodies (MAbs) and other recombinant proteins including difficult-to-express proteins such as plasma proteins, GPCRs and non-natural proteins such as fusion proteins. Selexis generated cell lines are being used in a variety of programs from drug discovery to a commercial product.

FOR MORE INFORMATION

  • Web        selexis.com    
  • LinkedIn        linkedin.com/company/selexis-sa
  • Twitter        twitter.com/SelexisSA
  • Facebook    facebook.com/SelexisSA

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Robert Meister
Follow us on
Visit website